Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy TRACON Pharmaceuticals stock

Own TRACON Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

TRACON Pharmaceuticals, Inc is a biotechnology business based in the US. TRACON Pharmaceuticals shares (TCON) are listed on the NASDAQ and all prices are listed in US Dollars. TRACON Pharmaceuticals employs 19 staff and has a market cap (total outstanding shares value) of USD$121.7 million.

How to buy shares in TRACON Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for TRACON Pharmaceuticals. Find the stock by name or ticker symbol: TCON. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until TRACON Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of TRACON Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of TRACON Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

TRACON Pharmaceuticals share price

Use our graph to track the performance of TCON stocks over time.

TRACON Pharmaceuticals shares at a glance

Information last updated 2020-11-27.
52-week range USD$0.95 - USD$10.108
50-day moving average USD$5.9747
200-day moving average USD$3.4202
Wall St. target price USD$7.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.016

Buy TRACON Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy TRACON Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TRACON Pharmaceuticals financials

Gross profit TTM USD$-14,530,000
Return on assets TTM -40.23%
Return on equity TTM -168.02%
Profit margin 0%
Book value $1.132
Market capitalisation USD$121.7 million

TTM: trailing 12 months

Shorting TRACON Pharmaceuticals shares

There are currently 214,987 TRACON Pharmaceuticals shares held short by investors – that's known as TRACON Pharmaceuticals's "short interest". This figure is 7.5% down from 232,299 last month.

There are a few different ways that this level of interest in shorting TRACON Pharmaceuticals shares can be evaluated.

TRACON Pharmaceuticals's "short interest ratio" (SIR)

TRACON Pharmaceuticals's "short interest ratio" (SIR) is the quantity of TRACON Pharmaceuticals shares currently shorted divided by the average quantity of TRACON Pharmaceuticals shares traded daily (recently around 826873.07692308). TRACON Pharmaceuticals's SIR currently stands at 0.26. In other words for every 100,000 TRACON Pharmaceuticals shares traded daily on the market, roughly 260 shares are currently held short.

However TRACON Pharmaceuticals's short interest can also be evaluated against the total number of TRACON Pharmaceuticals shares, or, against the total number of tradable TRACON Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TRACON Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 TRACON Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0167% of the tradable shares (for every 100,000 tradable TRACON Pharmaceuticals shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TRACON Pharmaceuticals.

Find out more about how you can short TRACON Pharmaceuticals stock.

TRACON Pharmaceuticals share dividends

We're not expecting TRACON Pharmaceuticals to pay a dividend over the next 12 months.

Have TRACON Pharmaceuticals's shares ever split?

TRACON Pharmaceuticals's shares were split on a 1:10 basis on 8 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TRACON Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for TRACON Pharmaceuticals shares which in turn could have impacted TRACON Pharmaceuticals's share price.

TRACON Pharmaceuticals share price volatility

Over the last 12 months, TRACON Pharmaceuticals's shares have ranged in value from as little as $0.95 up to $10.108. A popular way to gauge a stock's volatility is its "beta".

TCON.US volatility(beta: 1.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TRACON Pharmaceuticals's is 1.1359. This would suggest that TRACON Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

TRACON Pharmaceuticals overview

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site